AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Histone H2B type 1-C/E/F/G/I

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P62807

UPID:

H2B1C_HUMAN

Alternative names:

Histone H2B.1 A; Histone H2B.a; Histone H2B.g; Histone H2B.h; Histone H2B.k; Histone H2B.l

Alternative UPACC:

P62807; P02278; Q3B872; Q4VB69; Q93078; Q93080

Background:

Histone H2B type 1-C/E/F/G/I, known by alternative names such as Histone H2B.1 A and Histone H2B.a, plays a pivotal role in DNA packaging into chromatin, influencing transcription regulation, DNA repair, replication, and chromosomal stability. Its function extends to forming an antimicrobial barrier in the colonic epithelium and contributing to the bactericidal activity of amniotic fluid.

Therapeutic significance:

Understanding the role of Histone H2B type 1-C/E/F/G/I could open doors to potential therapeutic strategies, particularly in the realm of gene expression regulation and innate immunity.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.